GIP and GLP-1 receptor co-agonist
BGM0504 10 mg injection once weekly
BGM050_SC_10MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.72 (0.01 to 60.85) | 0.53 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 4.34 (0.20 to 79.58) | 0.20 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.55 (0.01 to 26.02) | 0.66 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 7.33 (1.47 to 38.61) | 0.10 |